Drugs / NP-015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00448253 | Jul 2007 → Aug 2008 | inhalational anthrax | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP-015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00448253 ↗ |
| Modality | Protein / enzyme biologic | “The test product is Anthrax Immune Globulin Intravenous (Human), NP-015.” NCT00448253 ↗ |
| Route | Intravenous | “NP-015 will be administered intravenously” NCT00448253 ↗ |